{"date":"2025-04-20","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6620-2025-04-20-1718-cj9tr2","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-04-20","time":"17:18:33","subject":"代子公司Handa Therapeutics, LLC公告簽訂治療血癌之505(b)(2)新藥, Phyrago之美國市場獨家銷售授權合約","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-04-20 17:18，「代子公司Handa Therapeutics, LLC公告簽訂治療血癌之505(b)(2)新藥, Phyrago之美國市」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}